Ceftriaxone
Treatment for Endocarditis
Typical Dosage: 2g IV once daily
Effectiveness
90%
Safety Score
70%
Clinical Trials
4
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
2g IV once daily
Time to Effect
3-6 days
Treatment Duration
2-6 weeks IV
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$900
Monitoring:$105,000
Side Effect Mgmt:$1,500
Total Annual:$107,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
1.3
Outcome-Based Costs
Cost per Responder
$126,353
Cost per Remission
$137,692
Ceftriaxone Outcomes
for Endocarditis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+78%
Common Side Effects
Diarrhea/GI upset
+7%
Rash/Hypersensitivity
+3%
Gallbladder sludge/pseudolithiasis
+1.5%
Increased LFTs
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Ceftriaxone in Endocarditis
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
NCT06423898RECRUITINGPHASE4
284 participants
INTERVENTIONAL
Alava, Spain +17 more
Started: Oct 9, 2024
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
NCT05156437ENROLLING BY INVITATIONPHASE4
20 participants
INTERVENTIONAL
Morgantown, United States
Started: Mar 16, 2022
Completed Clinical Trials
2 completed trials for Ceftriaxone in Endocarditis
Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
NCT03681431COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Seville, Spain
Started: Apr 23, 2018
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus
NCT02701595COMPLETEDPHASE3
324 participants
INTERVENTIONAL
Amiens, France +44 more
Started: Feb 29, 2016